MedTrace Logo

Oral Polypodium Leucotomos for Melasma

NCT01162850 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2011-08-05

No results posted yet for this study

Summary

Primary Objective: To determine whether there is improvement in the melasma of participants taking oral Polypodium Leucotomos Secondary Objective: To determine whether oral Polypodium Leucotomos is well tolerated in study subjects with melasma.

To determine whether treatment with Polypodium Leucotomos improves the health-related quality of life.

Conditions

  • Melasma

Interventions

DIETARY_SUPPLEMENT

Polypodium Leucotomos

Oral capsule at 240 mg taken twice a day for 12 weeks

DIETARY_SUPPLEMENT

Placebo

240 mg Placebo taken orally twice daily created by company which manufactured active ingredient

Sponsors & Collaborators

  • University of Miami

    lead OTHER

Principal Investigators

  • Heather Woolery-Lloyd, MD · University of Miami

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01162850 on ClinicalTrials.gov